Several common oncogenic pathways result in the overexpression of DNMT1, either via transcriptional or post-translational mechanisms [14]–[17] and targeting the DNMT1 isozyme for cancer therapy has been validated genetically. The gene discussed is DNMT1; the disease is cancer.